Brookline analyst Kumaraguru Raja initiated coverage of I-Mab (IMAB) with a Buy rating and $6 price target The firm says the company is advancing “differentiated” precision immunotherapies for the treatment of cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab Advances Precision Immuno-Oncology Pipeline with Strategic Focus
- I-Mab management to meet virtually with BTIG
- I-MAB Implements Workforce Reduction to Realign Operations
- I-Mab Biopharma Advances Precision Immuno-Oncology Programs Post-China Divestiture
- I-Mab Board Chairman to Acquire $2 Million in ADSs